STRESS PREDICTS TRAJECTORIES OF PSYCHOLOGICAL AND PHYSICAL FUNCTIONING IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Goyal, Neha [1 ]
Westbrook, Travis [2 ]
Andersen, Barbara L. [2 ]
机构：
[1] VA Palo Alto, Cupertino, CA USA
[2] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF BEHAVIORAL MEDICINE | 2016年 / 50卷
关键词：
D O I：
暂无
中图分类号：
B84 [心理学];
学科分类号：
04 ; 0402 ;
摘要：
D004
引用
下载
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [31] Pentostatin with an alkylating agents in refractory or relapsed chronic lymphocytic leukemia.
    Jajeh, A
    Ali, S
    Abboud, W
    Hadad, L
    Zalzaleh, G
    BLOOD, 2002, 100 (11) : 366B - 366B
  • [32] Identification of Therapeutic Targets for Chronic Lymphocytic Leukemia in the Relapsed and Refractory Setting
    Friedman, Daphne
    Weinberg, J. Brice
    Bond, Karen M.
    Volkheimer, Alicia D.
    Chen, Youwei
    Nevins, Joseph R.
    BLOOD, 2008, 112 (11) : 720 - 720
  • [33] MabThera® receives recommendation as therapy for relapsed or refractory chronic lymphocytic leukemia
    不详
    IMMUNOTHERAPY, 2009, 1 (05) : 731 - 731
  • [34] Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Barrett, Kathy
    Lu, Kai
    Jin, Hyun Yong
    Millen, Rosie
    Lefebure, Marcus
    Jiang, Yanwen
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Venetoclax Management and care for patients with relapsed or refractory chronic lymphocytic leukemia
    Paradis, Heather Brumbaugh
    Alter, Debbie
    Lterandi, Diane
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (05) : 604 - 610
  • [36] Acalabrutinib: a real breakthrough in the management of relapsed or refractory chronic lymphocytic leukemia?
    Nsiala, Laly
    Tomowiak, Cecile
    HEMATOLOGIE, 2020, 26 (03): : 146 - 147
  • [37] Efficacy Of Bendamustine and Rituximab In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Kataeva, Elena
    Golenkov, Anatoly
    Triphonova, Elena
    Dudina, Galina
    Mitina, Tatyana
    Lutskaya, Tatyana
    Vysotskaya, Ludmila
    Chernykh, Yulliya
    Zakharov, Sergey
    BLOOD, 2013, 122 (21)
  • [38] Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Amrein, Philip C.
    Attar, Eyal C.
    Takvorian, Tak
    Hochberg, Ephraim P.
    Ballen, Karen K.
    Leahy, Kathleen M.
    Fisher, David C.
    LaCasce, Ann S.
    Jacobsen, Eric D.
    Armand, Philippe
    Hasserjian, Robert P.
    Werner, Lillian
    Neuberg, Donna
    Brown, Jennifer R.
    CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2977 - 2986
  • [39] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [40] MabThera® receives recommendation as therapy for relapsed or refractory chronic lymphocytic leukemia
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (09) : 1192 - 1192
12345